Drug Combination Details
| General Information of the Combination (ID: C31005) | |||||
|---|---|---|---|---|---|
| Name | Resveratrol NP Info | + | Nutlin-3 Drug Info | ||
| Structure |
|
+ |
|
||
| Disease |
Ovarian cancer
[ICD-11: 2C73]
|
Investigative | [1] | ||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. Enhancing Drug Efficacy by This Combination | ||||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Experiment 1 Reporting the Effect of This Combination | [1] | |||||
| Molecule(s)
Regulation |
Up-regulation | Activity | CASP3 | Molecule Info |
Pathway MAP
|
|
| Biological
Regulation |
Up-regulation | Cytochrome c release | ||||
| In-vitro Model | A2780 | CVCL_0134 | Ovarian endometrioid adenocarcinoma | Homo sapiens | ||
| A2780/CP70 | CVCL_0135 | Ovarian endometrioid adenocarcinoma | Homo sapiens | |||
| Experimental
Result(s) |
Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. | |||||
| References | ||||
|---|---|---|---|---|
| Reference 1 | Treatment of ovarian cancer cells with nutlin-3 and resveratrol combination leads to apoptosis via caspase activation. J Med Food. Jan-Feb 2011;14(1-2):46-52. | |||
